Targeting CGRP Signaling Across Pain Disorders

Calcitonin gene related peptide (CGRP) is widely distributed in the human peripheral and central nervous system including pain pathways. Monoclonal antibodies against CGRP or its receptor have proved to be highly effective for the treatment of migraine. Equally important and in contrast to what could be expected from inhibiting a widely distributed peptide, the drugs are very well tolerated. In fact, the introduction of CGRP antibodies in the field of migraine has been among the largest gamechangers ever seen in the management of migraine. Data from controlled studies on treatment with CGRP antibodies in migraine as well as cluster headache, trigeminal neuralgia, posttraumatic headache, and osteoarthritis will be presented and discussed with the audience.